Ventricular Tachyarrhythmia (VT) Storm, Gene Expression in Implantable Cardioverter Defibrillator (ICD) Patients With Electrical Storm
This trial is active, not recruiting.
|Treatment||peripheral blood sampling|
|Sponsor||University of Pittsburgh|
|Start date||October 2005|
|End date||December 2016|
|Trial size||75 participants|
|Trial identifier||NCT00284453, 0510087|
The purpose of the proposed pilot study is to identify factors which are associated with periods of high ventricular arrhythmia burden. This will be performed by analysis of gene expression from peripheral blood samples.
time frame: Day 1 Enrollment
time frame: Day 90 +/- 30 days
Male or female participants at least 18 years old.
Inclusion Criteria: - ICD patients at least 18 years of age that present within a 72 hour period: 1) > 2 therapies for ventricular arrhythmias; 2) 1-2 therapies for ventricular arrhythmias; 3) inappropriate therapies for ventricular arrhythmias - Able to give informed consent Exclusion Criteria: - Inability to give informed consent
|Official title||Gene Expression in ICD Patients With Electrical Storm|
|Principal investigator||Sandeep K. Jain, M.D.|
|Description||This is a study of patients with ICD implants who present with multiple(>2), low-level(1-2) or inappropriate therapies to their defibrillator. The purpose of this pilot study is to identify factors which are associated with periods of high ventricular arrhythmia burden by looking at gene expression from peripheral blood, in addition to levels of known markers of CHF, including catecholamine levels, B-type natriuretic peptide, and troponin. This study hypothesizes that extrinsic or systemic factors play a role in triggering these events, and if true should yield candidate proteins which would spawn functional studies to prove a role in causation. Additionally, identification of a marker of increased recurrence of events may aid in guiding therapy (starting an anti-arrhythmic versus awaiting the next event).|
Call for more information